Medtronic Brain Modulation’s Post

Just published! Groundbreaking clinical findings in Brain Stimulation, the leading journal in neuromodulation. The analysis shows that lack of early symptom improvement with NeuroStar TMS (transcranial magnetic stimulation) does not predict final treatment outcome. Drawing from the world's largest depression outcomes registry, the NeuroStar Outcomes Registry, the study underscores the importance of completing the full treatment course of 36 NeuroStar TMS sessions for maximum benefit. Learn more about the effectiveness of TMS therapy sessions in our press release here: https://lnkd.in/gcKbSJ_B #NeuroStar #DepressionSupport #TMS

Happy to share our new paper on deep brain stimulation for tremor in patients with ventriculomegaly. In this report, we illustrate that VIM-DBS can provide an excellent tremor response in patients with medically intractable essential tremor, also in the context of marked ventriculomegaly. Immense thank you to all co-authors: Stijn Vandamme, Wim Maenhoudt, Stephanie Du Four, Jeroen Van Lerbeirghe, Dimitri Vanhauwaert, Olivier Van Damme For the full text, read below in Surgical Neurology International: https://lnkd.in/e_Ej2ai5

Movement disorders cannot be cured, both patients and caregivers are suffering from tremendous mental and physical stresses. SceneRay Corporation, Limited's development brings a new treatment option for patients, probably could help control the symptoms. #Qiming #QMPortfolio #Healthcare #SceneRay #DualTargetSTN #Axon8 #rechargeable #DeepBrainStimulationSystem #ClinicalUse #Medical #Launch #ParkinsonDisease #MovementDisorder

Personalized medicine could make the difference in treating #Parkinsons, including #genetherapy, addressing comorbidities, and cutting-edge therapies like deep brain stimulation. See what we found in our latest analysis of the research landscape: https://ow.ly/s78J50SEt6O #emergingscience

Deep brain stimulation (DBS) is an effective and safe medical treatment that improves the lives of patients with a wide range of neurological and psychiatric diseases, and has been consolidated as a first-line tool in the last two decades. Closed-loop deep brain stimulation (CLDBS) pushes this tool further by automatically adjusting the stimulation parameters to the brain response in real time. The main contribution of this paper is a low-size/power-controlled, compact and complete CLDBS system with two simultaneous acquisition channels, two simultaneous neurostimulation channels and wireless communication.

Deep brain stimulation (DBS) is used for multiple neurological conditions, including chorea. Prof. Elena Moro shares her experience and approach to treating choreic patients with DBS and how these methods have changed throughout the years. https://loom.ly/Dw5ff7s

HOW DO I GO ABOUT REFERRING A PATIENT FOR DBS? ⚡ If you have a patient who could benefit from deep brain stimulation (#DBS), but aren’t sure where to refer them, discover our Physician Locator tool, which enables you to find a suitable DBS expert: https://lnkd.in/eZuf45iR #BSCEMEA #DeepBrainStimulation #ParkinsonsAwarenessMonth

Medtech Insight digs into the study in #Alzheimers Research & Therapy showing statistically significant slowing in grey matter atrophy and increased brain connectivity after non-invasive precision #neuromodulation therapy. #DefaultModeNetwork #MedTech #ALZ #neurotech #ALZMoonshot

1. Neuromodulation technology is re-emerging as a treatment for various medical conditions, including Alzheimer’s, depression, and chronic pain. 2. Sinaptica Therapeutics is conducting a Phase 2 trial using repetitive transcranial magnetic stimulation for Alzheimer’s patients, showing a statistically significant improvement in cognitive and functional performance. 3. Patients treated with Sinaptica’s technology reported enhanced happiness and motivation, with effects lasting one year and minimal side effects. 4. Sinaptica plans to recruit around 300 patients for a Phase 3 trial next year. 5. Flow Neuroscience is using at-home transcranial direct current stimulation (tDCS) for treating depression, with Phase 2 trial results indicating a significant reduction in symptoms compared to a placebo. 6. The at-home approach of tDCS may increase accessibility for patients, although the effects can be minimal and vary between individuals. 7. Researchers at the University of Arizona are testing tDCS for pain management using the tKIWI device, which customizes electrical currents based on brain activity. 8. Ongoing research aims to understand the brain areas involved in pain perception and the potential for technology to alter neuronal firing patterns.